Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Synchrony Financial — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Synchrony Financial trades at $78.37 (market cap $25.53B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Synchrony Financial pays a 1.73% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SYF | |
|---|---|---|
Market Cap | $29.60B | $25.53B |
Sector | Health | Financials |
52-Week High | $491.22 | $88.47 |
52-Week Low | $205.48 | $63.78 |
Enterprise Value | $27.56B | — |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Synchrony Financial (SYF) trades at $78.78, up 0.75% today, with strong technical momentum as the stock tests resistance near $79. Recent earnings beats, including Q2 2026 EPS of $2.59 versus $2.14 expected, highlight robust fundamentals. The company maintains a net income margin of 23.4% and a low P/E of 8.05, signaling potential undervaluation. A new partnership with Stripe for CareCredit expansion and a $0.34 dividend reinforce positive business developments.
SYF presents a compelling investment case with analyst consensus bullish—62.5% buy ratings and an $86.33 price target imply ~10% upside. Risks include rising interest expenses of $4.14B and a projected negative net cash flow in 2026. Aggressive share buybacks and stable credit trends support upside, but macroeconomic pressures on consumer spending warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
